Neogen Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Neogen Corporation (NEOG) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.70% for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-07-30
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-08-31 was 1.90%, a 26.92% decline year-over-year.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-08-31 was 2.60%.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2013-08-31 was 0.80%.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2026 was 3.70%, a 0.00% change from fiscal 2025.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.70%, a 21.28% decline from fiscal 2024.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.70%, a 42.42% increase from fiscal 2023.
- Neogen Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.30%, a 725.00% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | 3.70% 10-K · filed 2026-07-30 | ||||
| 2025-05-31 | 3.70% 10-K · filed 2026-07-30 | ||||
| 2024-05-31 | 4.70% 10-K · filed 2026-07-30 | ||||
| 2023-05-31 | 3.30% 10-K · filed 2025-07-30 | ||||
| 2022-05-31 | 0.40% 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | 0.40% 10-Q · filed 2022-04-01 | ||||
| 2021-05-31 | 0.20% 10-K · filed 2023-08-15 | ||||
| 2021-02-28 | 0.20% 10-Q · filed 2021-03-31 | ||||
| 2020-11-30 | 0.20% 10-Q · filed 2020-12-29 | ||||
| 2020-08-31 | 1.90% 10-Q · filed 2020-09-30 | ||||
| 2020-05-31 | 1.90% 10-K · filed 2022-07-27 | ||||
| 2020-02-29 | 1.90% 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | 1.90% 10-Q · filed 2019-12-27 | ||||
| 2019-08-31 | 2.60% 10-Q · filed 2019-09-26 | ||||
| 2019-05-31 | 2.60% 10-K · filed 2021-07-30 | ||||
| 2018-05-31 | 1.60% 10-K · filed 2020-07-30 | ||||
| 2017-05-31 | 1.60% 10-K · filed 2019-07-30 | 1.20% 10-K · filed 2017-07-28 | |||
| 2016-05-31 | 1.20% 10-Q · filed 2017-03-31 | ||||
| 2015-05-31 | 1.20% 10-K · filed 2017-07-28 | ||||
| 2015-02-28 | 1.20% 10-Q · filed 2015-04-01 | ||||
| 2014-11-30 | 1.20% 10-Q · filed 2014-12-30 | ||||
| 2014-05-31 | 0.80% 10-K · filed 2016-07-29 | ||||
| 2014-02-28 | 0.80% 10-Q · filed 2014-04-04 | ||||
| 2013-11-30 | 0.80% 10-Q · filed 2014-01-09 | ||||
| 2013-08-31 | 0.80% 10-Q · filed 2013-09-30 | ||||
| 2013-05-31 | 1.20% 10-K · filed 2015-07-30 | ||||
| 2013-02-28 | 1.20% 10-Q · filed 2013-03-28 | ||||
| 2012-11-30 | 1.20% 10-Q · filed 2012-12-28 | ||||
| 2012-05-31 | 1.20% 10-K · filed 2014-07-30 | 1.17% 10-Q · filed 2011-12-30 | |||
| 2011-05-31 | 1.70% 10-K · filed 2013-07-30 | ||||
| 2010-05-31 | 2.00% 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |